ACM
BMRN icon

Argonaut Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Argonaut Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		$843K Hold
8,000
– – 2.83% 15
2015
Q2 		$1.09M Hold
8,000
– – 3.16% 15
2015
Q1 		$997K Buy
+8,000
New +$848K 1.6% 16

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Argonaut Capital Management's BMRN Position: Q3 2015 in Review

Argonaut Capital Management held its BioMarin Pharmaceuticals (BMRN) position steady in Q3 2015 at 8,000 shares worth $843K. The position accounts for 2.83% of the portfolio, ranked #15.

Argonaut Capital Management first reported a position in BMRN in Q1 2015 and has held it in 3 quarters since. The position peaked at $1.09M in Q2 2015. 393 funds tracked by Wall St. Rank hold BMRN as of Q3 2015.

  • Argonaut Capital Management held 8,000 shares of BioMarin Pharmaceuticals worth $843K as of Q3 2015.
  • Argonaut Capital Management left its BioMarin Pharmaceuticals share count unchanged in Q3 2015.
  • BioMarin Pharmaceuticals made up 2.83% of Argonaut Capital Management's portfolio in Q3 2015, its #15 holding.
  • Argonaut Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2015 and has held it in 3 quarters since.
  • Argonaut Capital Management's BioMarin Pharmaceuticals position peaked at $1.09M in Q2 2015.
  • 393 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2015.

Based on Argonaut Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.